{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:10:30Z","timestamp":1791951030003,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.euf.2025.03.011","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:37:58Z","timestamp":1743799078000},"page":"638-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metastasis-directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Marcin","family":"Miszczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Bilski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"K\u00f3i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Konat-B\u0105ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Suleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Hassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ch\u0142osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.03.011_b0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0090-4295(82)90462-9","article-title":"Long-term results following thoracotomy for metastatic bladder cancer","volume":"20","author":"Cowles","year":"1982","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.03.011_b0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0020","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/biomedicines12030519","article-title":"Revisiting treatment of metastatic urothelial cancer: where do cisplatin and platinum ineligibility criteria stand?","volume":"12","author":"Moussa","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.euf.2025.03.011_b0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint Inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0040","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2023.05.005","article-title":"Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology genitourinary faculty","volume":"84","author":"Bamias","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MOU.0000000000001184","article-title":"Defining oligometastatic state in uro-oncological cancers","volume":"34","author":"Fazekas","year":"2024","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.03.011_b0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.03.011_b0070","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.03.011_b0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.euf.2025.03.011_b0080","unstructured":"Rohatgi A. WebPlotDigitizer v.4.6 2022. https:\/\/automeris.io\/."},{"key":"10.1016\/j.euf.2025.03.011_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2025.03.011_b0090","unstructured":"Posit team. RStudio: integrated development environment for R. Boston, MA: Posit Software, PBC; 2024."},{"key":"10.1016\/j.euf.2025.03.011_b0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.euf.2025.03.011_b0100","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.03.011_b0105","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/sim.6111","article-title":"Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects","volume":"33","author":"Combescure","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2025.03.011_b0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ju.0000099823.60465.e6","article-title":"Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience","volume":"171","author":"Siefker-Radtke","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0115","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.eururo.2008.11.039","article-title":"Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30\/05)","volume":"55","author":"Lehmann","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1510\/icvts.2010.236687","article-title":"Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma","volume":"11","author":"Kanzaki","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.euf.2025.03.011_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.athoracsur.2011.03.097","article-title":"Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?","volume":"92","author":"Matsuguma","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.euf.2025.03.011_b0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5090\/kjtcs.2012.45.4.242","article-title":"Result of surgical resection for pulmonary metastasis from urothelial carcinoma","volume":"45","author":"Han","year":"2012","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.euf.2025.03.011_b0135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0140","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.clgc.2015.04.013","article-title":"Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.03.011_b0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.clgc.2017.04.007","article-title":"Consolidative radiotherapy in metastatic urothelial cancer","volume":"15","author":"Shah","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.03.011_b0150","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1245\/s10434-017-5970-8","article-title":"Oncologic outcome of metastasectomy for urothelial carcinoma: who is the best candidate?","volume":"24","author":"Nakagawa","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1055\/s-0036-1583271","article-title":"Long-term results and prognostic factors of pulmonary metastasectomy in patients with metastatic transitional cell carcinoma","volume":"65","author":"Luzzi","year":"2017","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.euf.2025.03.011_b0160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jjco\/hyz197","article-title":"Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy","volume":"50","author":"Abe","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0165","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.21037\/tau-19-624","article-title":"Metastasectomy of oligometastatic urothelial cancer: a single-center experience","volume":"9","author":"Muilwijk","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","article-title":"Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies","volume":"33","author":"Franzese","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.euf.2025.03.011_b0175","doi-asserted-by":"crossref","first-page":"790.e1","DOI":"10.1016\/j.urolonc.2021.05.005","article-title":"Metastasis-directed radiation therapy after radical cystectomy for bladder cancer","volume":"39","author":"Miranda","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0180","first-page":"71","article-title":"Resection of solitary lung metastasis of urinary tract transitional cell cancer can prolong survival in selected patients","volume":"150","author":"Ehle","year":"2025","journal-title":"Zentralbl Chir"},{"key":"10.1016\/j.euf.2025.03.011_b0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10147-011-0350-z","article-title":"Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?","volume":"18","author":"Bekku","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0190","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1055\/s-0041-1727150","article-title":"Metastases of urothelium carcinoma: differential diagnosis, resection, and survival","volume":"69","author":"Oguzhan","year":"2021","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.euf.2025.03.011_b0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13014-024-02465-y","article-title":"Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience","volume":"19","author":"Svedman","year":"2024","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0200","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.ju.0000067601.29966.4a","article-title":"Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?","volume":"169","author":"Sweeney","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0205","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.03.011_b0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/BLC-170108","article-title":"Survival after metastasectomy for metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"3","author":"Patel","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2025.03.011_b0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0220","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOU.0000000000001090","article-title":"PET in bladder cancer imaging","volume":"33","author":"Muin","year":"2023","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0225","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.eururo.2023.06.003","article-title":"Oligometastatic bladder cancer: defining a novel entity","volume":"84","author":"Labaki","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.011_b0230","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.3390\/cancers14102373","article-title":"Metastasis-directed radiation therapy with consolidative intent for oligometastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"14","author":"Longo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2025.03.011_b0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.euf.2025.03.011_b0240","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ijrobp.2015.07.2278","article-title":"Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403","volume":"93","author":"Nagata","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.03.011_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2016.08.015","article-title":"SPACE\u2014A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC","volume":"121","author":"Nyman","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0250","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.04.012","article-title":"Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases\u2014a pooled analysis of the German working group \u201cstereotactic radiotherapy.\u201d","volume":"97","author":"Rieber","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.euf.2025.03.011_b0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jrr\/rrv063","article-title":"Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study","volume":"57","author":"Aoki","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.euf.2025.03.011_b0260","doi-asserted-by":"crossref","unstructured":"Nuyttens JJ, van der Voort van Zyp NCMG, Verhoef C, et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys 2015;91:337\u201343.","DOI":"10.1016\/j.ijrobp.2014.10.021"},{"key":"10.1016\/j.euf.2025.03.011_b0265","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.21873\/anticanres.14164","article-title":"Stereotactic body radiotherapy for pulmonary oligometastases from esophageal cancer: results and prognostic factors","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euf.2025.03.011_b0270","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0275","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2024.03.013","article-title":"Activity of enfortumab vedotin and sacituzumab govitecan with radiation in preclinical models of bladder cancer","volume":"86","author":"Zhou","year":"2024","journal-title":"Eur Urology"},{"key":"10.1016\/j.euf.2025.03.011_b0280","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.011_b0285","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/cancers15041161","article-title":"Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis","volume":"15","author":"Aboudaram","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:30:45Z","timestamp":1768962645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2405456925000689"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.03.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastasis-directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}